Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Blakeman

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|April 5, 2022
Remote primary care during the COVID-19 pandemic for people experiencing homelessness: a qualitative studyKelly Howells, Mat Amp, Martin Burrows, et al.
BMC Medicine|May 31, 2018
Is telephone health coaching a useful population health strategy for supporting older people with multimorbidity? An evaluation of reach, effectiveness and cost-effectiveness using a 'trial within a cohort'Maria Panagioti, David Reeves, Rachel Meacock, et al.
Implementation Science : IS|April 28, 2019
Clinical Performance Feedback Intervention Theory (CP-FIT): a new theory for designing, implementing, and evaluating feedback in health care based on a systematic review and meta-synthesis of qualitative researchBenjamin Brown, Wouter T Gude, Thomas Blakeman, et al.
Journal of Multimorbidity and Comorbidity|May 11, 2026
Validation of the Global Treatment Burden Question (GTBQ): A novel single-item measure for use in clinical and research settingsChloe Gamlin, Rachel Johnson, Lauren J Scott, et al.
BJGP Open|November 28, 2019
Optimising Management of Patients with Heart Failure with Preserved Ejection Fraction in Primary Care (OPTIMISE-HFpEF): rationale and protocol for a multi-method studyFaye Forsyth, Jonathan Mant, Clare J Taylor, et al.
BJGP Open|June 9, 2023
Treatment burden in multiple long-term conditions: a mixed-methods study protocolRachel Johnson, Anastasiia G Kovalenko, Thomas Blakeman, et al.
Kidney International|August 14, 2024
Individual and neighborhood-level social and deprivation factors impact kidney health in the GLOMMS-CORE studySimon Sawhney, Iain Atherton, Thomas Blakeman, et al.
Frontiers in Psychiatry|December 20, 2021
Developing Best Practice Guidance for Discharge Planning Using the RAND/UCLA Appropriateness MethodNatasha Tyler, Claire Planner, Matthew Byrne, et al.
Trials|June 3, 2014
Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trialNathan R Hill, Daniel Lasserson, Ben Thompson, et al.
Trials|December 12, 2022
Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trialNathan R Hill, Daniel Lasserson, Ben Thompson, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|April 5, 2022
Remote primary care during the COVID-19 pandemic for people experiencing homelessness: a qualitative studyKelly Howells, Mat Amp, Martin Burrows, et al.
BMC Medicine|May 31, 2018
Is telephone health coaching a useful population health strategy for supporting older people with multimorbidity? An evaluation of reach, effectiveness and cost-effectiveness using a 'trial within a cohort'Maria Panagioti, David Reeves, Rachel Meacock, et al.
Implementation Science : IS|April 28, 2019
Clinical Performance Feedback Intervention Theory (CP-FIT): a new theory for designing, implementing, and evaluating feedback in health care based on a systematic review and meta-synthesis of qualitative researchBenjamin Brown, Wouter T Gude, Thomas Blakeman, et al.
Journal of Multimorbidity and Comorbidity|May 11, 2026
Validation of the Global Treatment Burden Question (GTBQ): A novel single-item measure for use in clinical and research settingsChloe Gamlin, Rachel Johnson, Lauren J Scott, et al.
BJGP Open|November 28, 2019
Optimising Management of Patients with Heart Failure with Preserved Ejection Fraction in Primary Care (OPTIMISE-HFpEF): rationale and protocol for a multi-method studyFaye Forsyth, Jonathan Mant, Clare J Taylor, et al.
BJGP Open|June 9, 2023
Treatment burden in multiple long-term conditions: a mixed-methods study protocolRachel Johnson, Anastasiia G Kovalenko, Thomas Blakeman, et al.
Kidney International|August 14, 2024
Individual and neighborhood-level social and deprivation factors impact kidney health in the GLOMMS-CORE studySimon Sawhney, Iain Atherton, Thomas Blakeman, et al.
Frontiers in Psychiatry|December 20, 2021
Developing Best Practice Guidance for Discharge Planning Using the RAND/UCLA Appropriateness MethodNatasha Tyler, Claire Planner, Matthew Byrne, et al.
Trials|June 3, 2014
Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trialNathan R Hill, Daniel Lasserson, Ben Thompson, et al.
Trials|December 12, 2022
Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trialNathan R Hill, Daniel Lasserson, Ben Thompson, et al.
Pageof 8